No association between elevated apoB or LDL-C and cardiovascular (CV) outcomes in patients taking pemafibrate in the PROMINENT trial has been identified, compared to those taking placebo. These findings cast doubt over the hypothesis that the failure to reduce CV events in the trial (despite a 26% reduction in TG) may have been linked to modest elevations in apoB and LDL-C.
Educational partners and supporters
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
